Tinsuneb 12,5; 25 or 50 mg Hard gelatin capsules
PDF Leaflet Revision Date: 17 September 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of GIST, MRCC, and pNET.
Dosage (summary)
GIST/MRCC: 50 mg daily for 4 weeks, then 2 weeks off; pNET: 37.5 mg daily.
Special Populations
- Elderly
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy; not recommended during breastfeeding.
Key Drug Interactions
- CYP3A4 inhibitors/inducers
- Anticoagulants
Contraindications
- Hypersensitivity to sunitinib
- Pregnancy
- Lactation
Common side effects
- Fatigue
- Hypertension
- Diarrhea
- Nausea
- Skin discoloration
Counselling Points
- Monitor blood pressure regularly
- Avoid pregnancy during treatment
- Report any signs of bleeding or severe skin reactions
Serious warnings
- Cerebrovascular events
- Severe cutaneous reactions
- Hemorrhage
- Gastrointestinal perforation
Important Disclaimer
The Tinsuneb 12,5; 25 or 50 mg Hard gelatin capsules professional information leaflet below is the property of Ranbaxy Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
